(Q39265565)

10 September 2017

title

Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer (English)

1 reference

10 September 2017

0 references

1 reference

1 reference

Jordi Codony-Servat

1

1 reference

10 September 2017

Mercedes Marín-Aguilera

2

1 reference

10 September 2017

Laura Visa

3

1 reference

10 September 2017

Xabier García-Albéniz

4

1 reference

10 September 2017

Estela Pineda

5

1 reference

10 September 2017

Pedro L Fernández

6

1 reference

10 September 2017

Xavier Filella

7

1 reference

10 September 2017

Pere Gascón

8

1 reference

10 September 2017

Begoña Mellado

9

1 reference

10 September 2017

publication date

4 October 2012

1 reference

10 September 2017

1 reference

10 September 2017

volume

73

1 reference

10 September 2017

issue

5

1 reference

10 September 2017

page(s)

512-521

1 reference

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Blockage of NF-kappaB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Identification of docetaxel resistance genes in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Nuclear factor-kappaB in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Interleukin-6 regulates androgen synthesis in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Inflammation and cancer: how friendly is the relationship for cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Tumor self-seeding by circulating cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Multiple transcription factors regulating the IL-6 gene are activated by cAMP in cultured Caco-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22591

21 January 2018

Identifiers

DOI

10.1002/PROS.22591

1 reference

10 September 2017

1 reference